or Try an Advanced Search...

    Anthrax Vaccines Stocks List

    Symbol Grade Name % Change
    EBS C Emergent Biosolutions, Inc. 19.57
    ALT D Altimmune, Inc. 2.05
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Anthrax Biodefense Biological Warfare Chemical Warfare Medicine Vaccines Athene Blood Plasma Chemical Warfare Agents Choline Cholinesterase Chronic Lymphocytic Leukemia Decontamination Drugs FDA Graft Versus Host Disease Host Disease Inflammatory Bowel Disease Influenza Lotion

    Related ETFs - A few ETFs which own one or more of the above listed Anthrax Vaccines stocks.

    Symbol Grade Name Weight
    OZEM F Roundhill GLP-1 & Weight Loss ETF 3.79
    LABD F Direxion Daily S&P Biotech Bear 3X Shares 0.96
    QQQS A Invesco NASDAQ Future Gen 200 ETF 0.51
    XBI A SPDR S&P Biotech ETF 0.36
    PRFZ A PowerShares FTSE RAFI US 1500 Small-Mid Portfolio 0.32
    View all Anthrax Vaccines ETFs...
    Compare ETFs
    Compare LABD to PRFZ Compare OZEM to XBI Compare QQQS to XBI

        Anthrax Vaccines Stocks Recent News

        Date Stock Title
        Nov 7 EBS Overdose Crisis In Shadows Of Elections As Black, Indigenous Americans Deaths Rise
        Nov 7 EBS Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
        Nov 7 ALT Altimmune, FDA agree on efficacy measures for phase 3 trial of pemvidutide
        Nov 7 EBS HubSpot Posts Better-Than-Expected Results, Joins Under Armour, Lyft, Wolverine World Wide, Zillow And Other Big Stocks Moving Higher On Thursday
        Nov 7 ALT Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity
        Nov 7 EBS New Strong Buy Stocks for November 7th
        Nov 7 EBS Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
        Nov 7 EBS Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript
        Nov 7 EBS Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript
        Nov 7 EBS Emergent BioSolutions Inc. 2024 Q3 - Results - Earnings Call Presentation
        Nov 6 EBS Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates
        Nov 6 EBS Emergent Biosolutions stock jumps 14% post-market on guidance raise
        Nov 6 EBS Emergent Biosolutions: Q3 Earnings Snapshot
        Nov 6 EBS Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa
        Nov 6 EBS Emergent Biosolutions non-GAAP EPS of $1.37 beats by $1.23, revenue of $293.8M misses by $3.7M
        Nov 6 EBS Emergent BioSolutions Reports Third Quarter 2024 Financial Results
        Nov 5 EBS Emergent Biosolutions Q3 2024 Earnings Preview
        Nov 4 EBS Emergent BioSolutions names Simon Lowry as chief medical officer
        Nov 4 EBS Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development
        Nov 4 ALT Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024
        Related Industries: Biotechnology
        Related Stock Lists: Anthrax Biodefense Biological Warfare Chemical Warfare Medicine Vaccines Athene Blood Plasma Chemical Warfare Agents Choline Cholinesterase Chronic Lymphocytic Leukemia Decontamination Drugs FDA Graft Versus Host Disease Host Disease Inflammatory Bowel Disease Influenza Lotion
        Anthrax Vaccines

        Anthrax vaccines are vaccines used to prevent anthrax. Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis. Vaccines are available for both humans and animals. The human anthrax vaccine is a killed vaccine, meaning it contains dead bacteria. It is given as a series of three injections over a six-month period.

        Browse All Tags